



CLIENT CODE: C000138394 CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI **NEW DELHI 110030** DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR PATIENT ID: PRIYF051094181

ACCESSION NO: 0181VJ000690 AGE: 28 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 14/10/2022 10:18 REPORTED: 29/10/2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

	EMOGLOBIN	11.7	Low	12.0 - 15.0	g/dL		
	METHOD : SLS- HEMOGLOBIN DETECTION METHOD	4.00		20.40			
	ED BLOOD CELL COUNT	4.38		3.8 - 4.8	mil/μL		
	METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION	4.40		4.0.40.0	He and to I		
	HITE BLOOD CELL COUNT	4.48		4.0 - 10.0	thou/µL		
	METHOD : FLUORESCENCE FLOW CYTOMETRY	224		450 440	He and to I		
	ATELET COUNT	234		150 - 410	thou/µL		
	METHOD: HYDRODYNAMIC FOCUSING BY DC DETECTION						
RBC AND PLATELET INDICES							
Н	EMATOCRIT	39.0		36.0 - 46.0	%		
	METHOD: CUMULATIVE PULSE HEIGHT DETECTION METHOD						
М	EAN CORPUSCULAR VOL	89.0		83.0 - 101.0	fL		
	METHOD: CALCULATED FROM RBC & HCT						
М	EAN CORPUSCULAR HGB.	26.7	Low	27.0 - 32.0	pg		
	METHOD: CALCULATED FROM THE RBC & HGB						
C	EAN CORPUSCULAR HEMOGLOBIN ONCENTRATION METHOD: CALCULATED FROM THE HGB & HCT	30.0	Low	31.5 - 34.5	g/dL		
М	ENTZER INDEX	20.3					
RI	ED CELL DISTRIBUTION WIDTH	12.6		11.6 - 14.0	%		
	METHOD: CALCULATED FROM RBC SIZE DISTRIBUTION CURVE						
М	EAN PLATELET VOLUME	10.9		6.8 - 10.9	fL		
	METHOD: CALCULATED FROM PLATELET COUNT & PLATELET HEMATO	CRIT					
WBC DIFFERENTIAL COUNT							
SI	EGMENTED NEUTROPHILS	51		40 - 80	%		
	METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING						
Al	BSOLUTE NEUTROPHIL COUNT	2.29		2.0 - 7.0	thou/µL		
	METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING						
LY	MPHOCYTES	39		20 - 40	%		
	METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING						
Al	BSOLUTE LYMPHOCYTE COUNT	1.74		1.0 - 3.0	thou/µL		
	METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING						
N	EUTROPHIL LYMPHOCYTE RATIO (NLR)	1.3					
E	OSINOPHILS	1		1 - 6	%		
	METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING						



Scan to View Report

Page 1 Of 12





CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

REPORTED:

PATIENT NAME: PRIYANKA MOHOLKAR

PATIENT ID:

PRIYF051094181

ACCESSION NO: 0181VJ000690

AGE: 28 Years

SEX: Female ABHA NO:

29/10/2022 16:28

DRAWN:

RECEIVED: 14/10/2022 10:18

REFERRING DOCTOR: SELF	CLIENT PATIENT ID:			
Test Report Status <u>Final</u>	Results	Biological Reference Interv	al Units	
ABSOLUTE EOSINOPHIL COUNT	0.03	0.02 - 0.50	thou/µL	
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES	9	2 - 10	%	
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE MONOCYTE COUNT	0.38	0.2 - 1.0	thou/µL	
METHOD: FLOW CYTOMETRY WITH LIGHT SCATTERING				
DIFFERENTIAL COUNT PERFORMED ON:	EDTA SMEAR			
MORPHOLOGY				
RBC	NORMOCYTIC NORM	OCHROMIC		
WBC	NORMAL MORPHOLO	OGY		
METHOD: MICROSCOPIC EXAMINATION				
PLATELETS	ADEQUATE			
ERYTHROCYTE SEDIMENTATION RATE (ESR),	-			
BLOOD				
SEDIMENTATION RATE (ESR)	06	0 - 20	mm at 1 hr	
METHOD: WESTERGREN METHOD				
GLUCOSE FASTING, FLUORIDE PLASMA				
GLUCOSE, FASTING, PLASMA	83	Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL	
METHOD: ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA BLOOD	WHOLE			
GLYCOSYLATED HEMOGLOBIN (HBA1C)	4.7	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%	
METHOD: HPLC				
MEAN PLASMA GLUCOSE	88.2	< 116.0	mg/dL	
METHOD: CALCULATED PARAMETER				
GLUCOSE, POST-PRANDIAL, PLASMA				
GLUCOSE, POST-PRANDIAL, PLASMA	91	70 - 139	mg/dL	
METHOD : ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
LIPID PROFILE, SERUM				
CHOLESTEROL	123	Desirable cholesterol level < 200	mg/dL	
		Borderline high cholesterol 200 - 239 High cholesterol > / = 240		



Page 2 Of 12 Scan to View Report





PRIYF051094181

CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

SEX: Female ABHA NO:

ACCESSION NO: 0181VJ000690 AGE: 28 Years

DRAWN: RECEIVED: 14/10/2022 10:18 REPORTED: 29/10/2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference Interv	al Units
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
TRIGLYCERIDES	67		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY			Very High: >/= 500	
HDL CHOLESTEROL	37	Low	Low HDL Cholesterol <40	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC			High HDL Cholesterol >/= 60)
CHOLESTEROL LDL	73		Adult levels: Optimal < 100 Near optimal/above optimal: 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL 100-
METHOD: ENZYMATIC COLORIMETRIC ASSAY				
NON HDL CHOLESTEROL	86		Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
CHOL/HDL RATIO	3.3		Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
LDL/HDL RATIO	2.0		0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk
VERY LOW DENSITY LIPOPROTEIN	13.4		< OR = 30.0	mg/dL
LIVER FUNCTION PROFILE, SERUM				
BILIRUBIN, TOTAL	0.36			mg/dL
BILIRUBIN, DIRECT	0.17		< 0.30	mg/dL
BILIRUBIN, INDIRECT	0.19		0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: COLORIMETRIC	7.7		6.0 - 8.0	g/dL
ALBUMIN METHOD: COLORIMETRIC	4.8		3.97 - 4.94	g/dL
GLOBULIN	2.9		2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.7		1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: UV ABSORBANCE	19		< OR = 35	U/L

Scan to View Details

Scan to View Report

Page 3 Of 12





CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL)
F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower,Hari Niwas, LBS Marg THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

PRIYF051094181

DRAWN:

ACCESSION NO: 0181VJ000690

AGE: 28 Years SEX: Female

RECEIVED: 14/10/2022 10:18

ABHA NO:

REPORTED:

29/10/2022 16:28

REFERRING DOCTOR: SELF

CLIENT PATIENT ID:

PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	Interval Units
ALANINE AMINOTRANSFERASE (ALT/SGPT)	13		< OR = 35	U/L
METHOD : UV ABSORBANCE	65		25 404	11/1
ALKALINE PHOSPHATASE	65		35 - 104	U/L
METHOD : COLORIMETRIC	0		0 - 40	11/1
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: ENZYMATIC, COLORIMETRIC	9		0 - 40	U/L
ACTATE DEHYDROGENASE	159		125 - 220	U/L
METHOD: UV ABSORBANCE	133		125 220	0/ L
BLOOD UREA NITROGEN (BUN), SERUM				
BLOOD UREA NITROGEN	8		6 - 20	mg/dL
METHOD : ENZYMATIC ASSAY				
CREATININE, SERUM				
CREATININE	0.52		0.5 - 0.9	mg/dL
METHOD : COLORIMETRIC				2.
BUN/CREAT RATIO				
BUN/CREAT RATIO	15.38	High	8.0 - 15.0	
URIC ACID, SERUM				
JRIC ACID	2.8		2.4 - 5.7	mg/dL
METHOD: ENZYMATIC COLORIMETRIC ASSAY				2.
TOTAL PROTEIN, SERUM				
TOTAL PROTEIN	7.7		6.0 - 8.0	g/dL
METHOD: COLORIMETRIC				
ALBUMIN, SERUM				
ALBUMIN	4.8		3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
GLOBULIN				
GLOBULIN	2.9		2.0 - 3.5	g/dL
ELECTROLYTES (NA/K/CL), SERUM				
SODIUM	136		136 - 145	mmol/L
POTASSIUM	3.88		3.5 - 5.1	mmol/L
CHLORIDE	100		98 - 107	mmol/L
PHYSICAL EXAMINATION, URINE				
COLOR	PALE YELLOW			
METHOD: VISUAL INSPECTION				
APPEARANCE	CLEAR			
METHOD: VISUAL INSPECTION				
SPECIFIC GRAVITY	1.005		1.003 - 1.035	



Page 4 Of 12 Scan to View Report





CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

PRIYF051094181

DRAWN:

ACCESSION NO: 0181VJ000690

<u>Final</u>

AGE: 28 Years SEX: Female ABHA NO:

REPORTED:

29/10/2022 16:28

Test Report Status

RECEIVED: 14/10/2022 10:18

CLIENT PATIENT ID:

PATIENT ID:

METHOD: IONIC CONCENTRATION METHOD

REFERRING DOCTOR: SELF

CHEMICAL EXAMINATION, URINE

PΗ

METHOD: DOUBLE INDICATOR PRINCIPLE

PROTFIN

METHOD: TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID

GLUCOSE

METHOD: GLUCOSE OXIDASE PEROXIDASE

KETONES METHOD: NITROPRUSSIDE REACTION

BLOOD

METHOD : PEROXIDASE

UROBILINOGEN METHOD: MODIFIED EHRLICH REACTION

NITRITE

METHOD: 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL

LEUKOCYTE ESTERASE

MICROSCOPIC EXAMINATION, URINE

PUS CELL (WBC'S)

METHOD: MICROSCOPIC EXAMINATION EPITHELIAL CELLS

METHOD: MICROSCOPIC EXAMINATION

ERYTHROCYTES (RBC'S)

METHOD: MICROSCOPIC EXAMINATION

CASTS

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS

METHOD: MICROSCOPIC EXAMINATION

BACTERIA

METHOD: MICROSCOPIC EXAMINATION

YEAST

THYROID PANEL, SERUM

T3 METHOD: ELECTROCHEMILUMINESCENCE

T4

METHOD : ELECTROCHEMILUMINESCENCE

TSH 3RD GENERATION

METHOD: ELECTROCHEMILUMINESCENCE

Results

Biological Reference Interval

Units

5.5

4.7 - 7.5

NOT DETECTED

NOT DETECTED

NOT DETECTED NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

144.0

8.87

1.380

NORMAL

2-3

1-2

NOT DETECTED

NOT DETECTED

NORMAL

NOT DETECTED

NOT DETECTED

0-5

/HPF

0 - 5

/HPF

NOT DETECTED

/HPF

NOT DETECTED

NOT DETECTED

ng/dL

80 - 200

0.27 - 4.2

5.1 - 14.1 μg/dL

µIU/mL

Scan to View Details

Page 5 Of 12 Scan to View Report





PRIYF051094181

CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA

8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

PATIENT ID:

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

ACCESSION NO: 0181VJ000690 AGE: 28 Years ABHA NO: SEX: Female

DRAWN: RECEIVED: 14/10/2022 10:18 REPORTED: 29/10/2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Units Test Report Status Biological Reference Interval <u>Final</u>

PAPANICOLAOU SMEAR

TEST METHOD CONVENTIONAL GYNEC CYTOLOGY

METHOD: MICROSCOPIC EXAMINATION

SPECIMEN TYPE P-1201/22

TWO UNSTAINED CERVICAL SMEARS RECEIVED

METHOD: MICROSCOPIC EXAMINATION

REPORTING SYSTEM 2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY

SPECIMEN ADEQUACY SATISFACTORY

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

MICROSCOPY THE SMEARS SHOW MAINLY SUPERFICIAL SQUAMOUS CELLS, FEW

INTERMEDIATE SQUAMOUS CELLS IN THE BACKGROUND OF FEW

POLYMORPHS.

METHOD: PAP STAIN

INTERPRETATION / RESULT NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

METHOD: PAP STAIN & MICROSCOPIC EXAMINATION

Comments

PLEASE NOTE PAPANICOLAU SMEAR STUDY IS A SCREENING PROCEDURE FOR CERVICAL CANCER WITH INHERENT FALSE NEGATIVE RESULTS HENCE SHOULD BE INTERPRETED WITH CAUTION. NO CYTOLOGICAL EVIDENCE OF HPV INFECTION IN THE SMEARS STUDIED. SMEARS WILL BE PRESERVED FOR 5 YEARS ONLY.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A

METHOD: GEL COLUMN AGGLUTINATION METHOD.

RH TYPE POSITIVE

METHOD: GEL COLUMN AGGLUTINATION METHOD.

XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO **NEGATIVE**

ECG

FCG WITHIN NORMAL LIMITS

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT RELEVANT PAST HISTORY PAST H/O ANAEMIA

RELEVANT PERSONAL HISTORY MARRIED / VEG. DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL.

MENSTRUAL HISTORY (FOR FEMALES) REGULAR 28-32/3-5

LMP (FOR FEMALES) 26/09/2022



Page 6 Of 12





Units

CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

ABHA NO:

PATIENT ID: PRIYF051094181

DRAWN:

ACCESSION NO: 0181VJ000690

RECEIVED: 14/10/2022 10:18

SEX: Female

REPORTED: 29/10/2022 16:28

REFERRING DOCTOR: SELF

CLIENT PATIENT ID:

Results **Biological Reference Interval** Test Report Status <u>Final</u>

OBSTETRIC HISTORY (FOR FEMALES) A1,L0

RELEVANT FAMILY HISTORY FATHER:-HIGH BLOOD PRERSSURE

AGE: 28 Years

HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.58 mts WEIGHT IN KGS. 45 Kgs

BMI 18 BMI & Weight Status as follows: kg/sqmts Below 18.5: Underweight

18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL PHYSICAL ATTITUDE NORMAL GENERAL APPEARANCE / NUTRITIONAL STATUS HEALTHY BUILT / SKELETAL FRAMEWORK **AVERAGE** FACIAL APPEARANCE NORMAL NORMAL SKIN UPPER LIMB NORMAL LOWER LIMB NORMAL NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL **TEMPERATURE** NORMAL

PULSE 72/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID

BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

110/70 MM HG BP mm/Hg (SUPINE)

> NORMAL NORMAL NORMAL

> > ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST NORMAL



PERICARDIUM

HEART SOUNDS

APEX BEAT

MURMURS

Page 7 Of 12

Scan to View Report





CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

PATIENT ID:

PRIYF051094181

ACCESSION NO: 0181VJ000690 AGE: 28 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 14/10/2022 10:18 REPORTED: 29/10/2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Units Test Report Status **Biological Reference Interval** <u>Final</u>

MOVEMENTS OF CHEST SYMMETRICAL

BREATH SOUNDS INTENSITY NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL VENOUS PROMINENCE ABSENT

LIVER NOT PALPABLE **SPLEEN** NOT PALPABLE

HERNIA ABSENT

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL CRANIAL NERVES NORMAL CEREBELLAR FUNCTIONS NORMAL SENSORY SYSTEM NORMAL MOTOR SYSTEM NORMAL REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA NORMAL **EYELIDS** NORMAL EYE MOVEMENTS NORMAL CORNEA NORMAL

DISTANT VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT DISTANT VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT NEAR VISION RIGHT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT NEAR VISION LEFT EYE WITHOUT GLASSES WITHIN NORMAL LIMIT

COLOUR VISION NORMAL

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT



Page 8 Of 12 Scan to View Report





CLIENT CODE: C000138394

CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN - U74899PB1995PLC045956

PATIENT ID:

CLIENT PATIENT ID:

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

PRTYF051094181

ACCESSION NO:

0181VJ000690

AGE: 28 Years SEX: Female

ABHA NO:

REPORTED:

29/10/2022 16:28

DRAWN:

RECEIVED: 14/10/2022 10:18

Test Report Status

REFERRING DOCTOR: SELF

<u>Final</u>

Results

Units **Biological Reference Interval**

REMARKS / RECOMMENDATIONS

GYNAEC CONSULT FOR CANDIDIAL VAGINITIS IRON RICH DIET ADVISED. ADD GREEN LEAFY VEGETABLES, DATES BEETROOT TO THE DAILY DIET. TO DO S.IRON STUDIES AND HB ELECTROPHORESIS AND PHYSICIAN'S

CONSULT FOR TREATMENT OF ANAEMIA.

USG -CANCEL

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-

Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait <13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR); as test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis)

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:



Page 9 Of 12 Scan to View Report





CLIENT CODE: C000138394

CLIENT'S NAME AND ADDRESS:

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

PRTYF051094181

ACCESSION NO:

0181VJ000690

AGE: 28 Years SEX: Female

ABHA NO: REPORTED:

29/10/2022 16:28

DRAWN:

RECEIVED: 14/10/2022 10:18

CLIENT PATIENT ID:

PATIENT ID:

Test Report Status

REFERRING DOCTOR: SELF

<u>Final</u>

Results

Units **Biological Reference Interval**

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes.
- 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods,falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin en viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin en viral hepatitis disease (direct) bilirubin en viral hepatitis direction en viral hepatitis en viral hepatitis en viral hepatitis en viral hepatit there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,
Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
 Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
- · Muscle problems, such as breakdown of muscle fibers
- · Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy URIC ACID, SERUM-

Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and



Page 10 Of 12 Scan to View Report







CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

SOUTH WEST DELHI NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg THANE, 400602

MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

PATIENT ID: PRIYF051094181

0181VJ000690 AGE: 28 Years SEX: Female ABHA NO: ACCESSION NO:

DRAWN: RECEIVED: 14/10/2022 10:18 REPORTED: 29/10/2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Results Test Report Status Biological Reference Interval Units <u>Final</u>

globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome,Protein-losing enteropathy etc.

ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc. ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

HISTORY-* THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession

Scan to View Details







PRIYF051094181

CLIENT CODE: C000138394 **CLIENT'S NAME AND ADDRESS:**

ACROFEMI HEALTHCARE LTD (MEDIWHEEL) F-703, F-703, LADO SARAI, MEHRAULI

ACCESSION NO: 0181VJ000690

SOUTH WEST DELHT NEW DELHI 110030 DELHI INDIA 8800465156

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602 MAHARASHTRA, INDIA

Tel: 9111591115, Fax: CIN-U74899PB1995PLC045956

PATIENT ID:

Email: customercare.thane@srl.in

PATIENT NAME: PRIYANKA MOHOLKAR

AGE: 28 Years SEX: Female ABHA NO:

DRAWN: RECEIVED: 14/10/2022 10:18 REPORTED: 29/10/2022 16:28

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Biological Reference Interval Units <u>Final</u>

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



